Circular dumbbell miR-34a-3p and -5p suppresses pancreatic tumor cell-induced angiogenesis and activates macrophages

MANU GNANAMONY1, LUSINE DEMIRKHANYAN2, LIANG GE3, PARESH SOJITRA4, SNEHA BAPANA2, JOSEPH A. NORTON2 and CHRISTOPHER S. GONDI2,5,6

Departments of 1Pediatrics and 2Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605; 3University of Pittsburgh Medical Center, Presbyterian University Hospital, Pittsburgh, PA 15213; 4Sanford Center for Digestive Health, Sioux Falls, SD 57105; Departments of 5Surgery and 6Pathology, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA

Received November 6, 2019; Accepted October 2, 2020

DOI: 10.3892/ol.2020.12336

Abstract. Angiogenesis is a tightly regulated biological process by which new blood vessels are formed from pre-existing blood vessels. This process is also critical in diseases such as cancer. Therefore, angiogenesis has been explored as a drug target for cancer therapy. The future of effective anti-angiogenic therapy lies in the intelligent combination of multiple targeting agents with novel modes of delivery to maximize therapeutic effects. Therefore, a novel approach is proposed that utilizes dumbbell RNA (dbRNA) to target pathological angiogenesis by simultaneously targeting multiple molecules and processes that contribute to angiogenesis. In the present study, a plasmid expressing miR-34a-3p and -5p dbRNA (db34a) was constructed using the permuted intron-exon method. A simple protocol to purify dbRNA from bacterial culture with high purity was also developed by modification of the RNASwift method. To test the efficacy of db34a, pancreatic cancer cell lines Panc-1 and Mia PaCa-2 were used. Functional validation of the effect of db34a on angiogenesis was performed on human umbilical vein endothelial cells using a tube formation assay, in which cells transfected with db34a exhibited a significant reduction in tube formation compared with cells transfected with scrambled dbRNA. These results were further validated in vivo using a zebrafish angiogenesis model. In conclusion, the present study demonstrates an approach for blocking angiogenesis using db34a. The data also show that this approach may be used to targeting multiple molecules and pathways.

Introduction

Metastatic tumors are usually highly vascularized, and this increased vascularity aids the dissemination of tumor cells to promote metastatic events. This high vascularity is induced via the expression of pro-angiogenic cytokines, which promote the development of abnormal tumor vasculature. The abnormal vasculature is characterized by hyperpermeable vessels, increased vessel diameter and abnormally thickened basement membranes. All these factors contribute to tumor growth (1-4). Several anti-angiogenic agents, such as bevacinumab, sunitinib and vatalanib have been developed to target increased tumor vascularity (5). The goal of anti-angiogenic therapy is the obliteration of tumor-induced vasculature with the aim of decreasing vascular permeability and the perfusion of oxygen and nutrients to tumor cells. This approach has often been termed as ‘tumor starvation’. A converse approach to anti-angiogenic therapy is the use of agents to stabilize abnormal tumor vasculature by reducing blood vessel diameter and permeability, controlling vessel perfusion, reducing tumor interstitial pressure and improving tumor oxygenation with the aim of reducing tumor hypoxia and thereby controlling metastasis (6-9). Researchers have even suggested that anti-angiogenic therapy may transiently normalize tumor vasculature and its microenvironment, thus enhancing the efficacy of chemoradiotherapy (10). Unfortunately, both these approaches have failed to achieve a clinically relevant standing despite the vast amount of research being conducted. The main drawback of these approaches is that they have been directed at single targets and have not produced clinically consistent desirable outcomes. In the present study, the targeting of multiple pro-angiogenic cytokines to achieve a complete anti-angiogenic outcome is proposed. This multipronged approach aims to exploit the microRNA (miRNA, miR) machinery to attain a clinically desirable outcome. The present study may pave the way for the development of a multi-targeted strategy, as well as methodologies that could be applicable to numerous other disease conditions.

The use of RNA molecules to target angiogenesis is not new (11-14). Various approaches have been developed to target angiogenesis, including the use of RNA aptamers, miRNAs,
small interfering RNAs (siRNAs) and combinations thereof. Although promising, the half-life of RNA molecules is very short. *In vitro*, natural RNA exhibits a half-life of a few seconds to a few minutes in various biological fluids, including human serum, whereas RNAs partially modified at the 20th position have extended half-lives of 5 sec to 15 h (15). An RNA-based anti-angiogenesis drug called Macugen has these modifications; however, although somewhat successful, it is limited in addressing the problem of angiogenesis (16). The approach used in the present study is the development of a closed circular RNA having multiple double-stranded regions coding for miRNAs, which are interrupted by loops or dumbbells. Using a circular RNA should eliminate exonuclease activity while double-stranded RNA (dsRNA), being inherently more stable than single-stranded RNA (ssRNA), should contribute to an increased half-life. To the best of our knowledge, this is the first attempt to use closed circular dumbbell RNAs (dbRNAs) to code for miRNAs/siRNAs with a therapeutic intention. The study uses miR-34a-3p and -5p in a circular form.

Materials and methods

Construction of dbRNAs. The permuted intron-exon (PIE) method was used, which is an enzyme-free RNA circularization method based on group I intron self-splicing (17). Circularization is triggered by the presence of magnesium ions and guanine nucleotides, and the production of circular RNA can be conducted using essentially any type of cell (17-19). A previously described strategy was used, in which recombinant RNA is disguised as a natural RNA and thus appropriates the host machinery to evade cellular RNases (20), but with an added RNA circularization step using the rrrC terminator (21). Sequences coding for miR-34a-3p and -5p (db34a) and its scrambled sequence (dbSCR) were synthesized with the lpp promoter and the rrrC terminator sequences (Fig. 1A and B), and inserted in pUC57-Kan plasmids (GenScript Biotech). The JM101Tr E. coli strain [Δlac pro], supE, thi, recA56, srl-300. was used for the isolation of cells) were spun down (3,000 x g for 25 min at 4°C to precipitate the small RNAs, which included the dbRNA product. The small RNA was washed twice with ice-cold 75% ethanol and then dissolved in sterile water. The purity of the small RNA was verified in a 1% agarose gel. The quality of RNA was determined using a NanoDrop™ spectrophotometer.

Purification of dbRNAs. The isolated small RNAs were separated on a 15% urea-polyacrylamide gel (PAGE). The gel was stained with ethidium bromide (0.5 mg/ml) for 15 min at room temperature and then destained by washing with distilled water twice. The gel portion containing the dbRNA was excised with a sharp scalpel and the RNA was purified using the ZR Small-RNA PAGE Recovery Kit (Zymo Research Corp.) according to the manufacturer's instructions. RNA quality and quantity were measured using a NanoDrop spectrophotometer.

Verification of dbRNA specificity. The isolated dbRNAs were separated on a 15% urea-PAG (TBE is the running buffer) at 20 mA followed by bloting using the iBlot™ Gel Transfer Device onto a Novex™ iBlot™ DNA Transfer Stack with a nylon membrane (both Invitrogen; Thermo Fisher Scientific, Inc.). Northern blot analysis was conducted using a miR-34a specific biotinylated probe (sequence: 5′Biog/AGGGCAGTATACTTGCTGAT) after membrane was incubated with prehybridization buffer (6X SSC buffer, 10X Denhardt’s solution, 0.2% SDS; MilliporeSigma) for 1 h at 42°C on rotating shaker following 3 day incubation with hybridization buffer (6X SSC buffer, 5X Denhardt’s solution, 0.2% SDS; MilliporeSigma) with probe at the same conditions. The chemiluminescent signal was detected using a Pierce™ Chemiluminescent Nucleic Acid Detection Module kit (Thermo Fisher Scientific, Inc.) according to the manufacturer’s recommendations.

Determining the RNase A resistance of db34a RNA. To determine the resistance of db34a to RNase A, 1 µg total RNA from bacteria transformed with db34a-expressing plasmid was isolated and incubated with or without 0.7x10⁵ U/µl RNAse-A for 24 h in four independent treatments at room temperature. Since the bacterial lipoprotein (lpp) promoter (18,24) is a constitutive bacterial promoter that drives the expression of bacterial lpp, bacterial lpp RNA was used as the linear control for db34a. First, cDNA was synthesized using miScript II RT kit (Qiagen GmbH) using conditions: 37°C for 60 min and 95°C for 5 min from untreated and 24 h RNase A treated samples followed by quantitative PCR (qPCR) with the following primers: lpp forward, CTGTCCTCTGACGTTCACTC and lpp reverse, ACGAGCTGCATCATCTTTAG. Expression of db34a was measured by qPCR with miR-34a specific primers [5′UGCAGUGUCUAGCGUGUGU, cat. no. 218300; Hs_miR-34a_1 miScript Primer Assay (forward primer) and miScript Universal Primer (reverse)] using the miScript SYBR Green PCR Kit (Qiagen GmbH). The qPCR conditions used were as follows: Initial heat activation 95°C for 15 min, followed by denaturation at 94°C for 15 sec, annealing at 55°C for 30 sec and extension at 70°C for 30 sec, for 40 cycles. Four independent experiments with three replicates in each experiment were performed. ΔCq was calculating by subtracting the average Cq values of lpp from db34a for both untreated (control) and RNase A treated cells. ΔΔCq values were
obtained by subtracting the average ΔCq of the control group from both the control and treatment ΔCq data followed by the calculation of $2^{-\Delta\Delta Cq}$ (25). The difference between treated and control groups with reference to db34a/lpp RNA was analyzed using one-way ANOVA.

Cell culture conditions. The MIA PaCa-2 and PANC-1 pancreatic cancer cell lines were obtained from American Type Culture Collection (ATCC) and maintained under the conditions recommended by the supplier. Cells were grown in tissue culture-treated Petri plates in RPMI-1640 medium (Thermo Fisher Scientific, Inc.) with 10% FBS (VWR Corporation) and 1% penicillin-streptomycin (Thermo Fisher Scientific Inc.) in a humidified 5% CO₂ atmosphere at 37°C. To evaluate immune activation, J774A.1 mouse macrophages obtained from ATCC were used. The macrophages were grown in tissue culture-treated Petri plates in DMEM (Thermo Fisher Scientific Inc.) with 10% FBS and 1% penicillin-streptomycin. Human umbilical vein endothelial cells (HUVECs) were obtained from Thermo Fisher Scientific, Inc. and cultured in Medium 200 with 1X low serum growth supplement (Thermo Fisher Scientific Inc.). HUVECs with a low passage number (3 passages) were used for the tube formation assay as described in a previous study (26).

Angiogenesis antibody array. An angiogenic antibody analysis was performed using a RayBio® Human Angiogenesis Array C1 kit (AAH-ANG-1; RayBiotech, Inc.) according to the manufacturer’s instructions. In brief, MIA PaCa-2 and PANC-1 cells were seeded (1.2x10⁶/well; 6-well plate) in tissue culture-treated Petri plates overnight in RPMI-1640 medium (Thermo Fisher Scientific Inc.) with 10% FBS (VWR Corporation) and 1% penicillin-streptomycin (Thermo Fisher Scientific Inc.) in a humidified 5% CO₂ atmosphere at 37°C. The cells were transfected with 4 µg of db34a or dbSCR using jetPRIME transfection reagent (Polyplus-transfection SA at 37°C) or remained untransfected (control). A mouse inflammation array analysis was performed using a RayBio Mouse Inflammation Array C1 kit (cat. no. AAM-INF-1; RayBiotech, Inc.) according to the manufacturer’s instructions. In brief, MIA PaCa-2 and PANC-1 cells were seeded (1.2x10⁶/well; 6-well plate) and cultured overnight in RPMI-1640 medium (Thermo Fisher Scientific Inc.) supplemented with 10% FBS (VWR Corporation) and 1% penicillin-streptomycin (Thermo Fisher Scientific Inc.) in a humidified 5% CO₂ atmosphere at 37°C. The next day, cells were transfected with 4 µg of db34a or dbSCR at 37°C using jetPRIME transfection reagent or remained untransfected (control). After 20 h, the medium was replaced with serum-free medium RPMI-1640 (Thermo Fisher Scientific Inc.) and the plates were incubated for another 16 h. Conditioned medium was then collected after centrifugation at 16,000 x g at 4°C for 10 min and transferred to freshly grown macrophages. After overnight incubation at 37°C, the macrophages were lysed with lysis buffer provided with kit and equal samples from each condition with regard to total protein quantity (100 µg per sample; total protein concentration was determined by Pierce 660 nm Protein Assay (Thermo Fisher Scientific Inc.) applied to the antibody-spotted membranes. Following overnight incubation at 4°C, the membranes were washed and 1 ml diluted biotin-conjugated antibody mix was added to the membranes, which were kept at room temperature for 2 h. After several washes, the membranes were incubated with diluted HRP-conjugated streptavidin for 2 h. Detection was performed using ECL protocols in which the membranes were exposed to X-ray films to detect the binding of inflammatory factors. Spot intensities were quantified using ImageJ version 1.52a software. Significant differences between macrophages grown in dbSCR and db34a conditioned media were identified using one-way ANOVA.

In vitro angiogenic assay. To determine the anti-angiogenic effect of the dbRNA molecules, an endothelial cell tube formation assay was conducted using HUVECs as previously described (26). Briefly, HUVECs were stained with 2 µg/ml cell-permeant fluorescent dye (calcein-AM; Thermo Fisher Scientific, Inc.) with incubation at 37°C in the dark for ≥30 min. A Gelrex basement membrane matrix (Thermo Fisher Scientific, Inc; 40 µl) was applied to 96-well plates and allowed to solidify for 30 min at room temperature. The stained HUVECs were trypsinized, re-suspended in serum-free medium (Gibco Medium 200PR; Gibco; Thermo Fisher Scientific Inc.) and plated at a density of 20,000 cells/well in 100 µl conditioned medium from the db34a and dbSCR transfected cells. HUVECs in complete medium (Gibco Medium 200PRF supplemented with Gibco Low Serum Growth Supplement; Gibco; Thermo Fisher Scientific Inc.) were used as controls. The plates were incubated at 37°C in a humidified incubator for 3 h. The formation of angiogenic network was visualized at x10 magnification using an inverted fluorescence microscope and quantified by ImageJ version 1.52a (n=17). The significance of difference of each HUVEC treatment group compared to control was determined using one-way ANOVA.

Zebrafish aquaculture. Transgenic VEGFR2:green-reef coral fluorescent protein (G-RCFP) zebrafish (Danio rerio) that express G-RCFP under the control of a VEGFR2/KDR promoter were obtained from ZFIN (y1Tg). The fish were maintained under standard aquaculture conditions in a circulating
GNANAMONY et al: db34a MEDIATES ANGIGENIC SUPPRESSION AND MACROPHAGE ACTIVATION

Tank system constructed as previously described (27), and according to protocols approved by the Institutional Animal and Use Committee (IACUC) of University of Illinois College of Medicine at Peoria. Water was purified by a reverse osmosis system and supplemented with sea salts at concentration of 60 mg/l in order to provide the trace minerals that the fish required. The pH of the water was maintained between 7.6 and 8.5 by the addition of sodium bicarbonate. All experimental procedures using zebrfish were performed with approval from the IACUC of University of Illinois College of Medicine at Peoria.

In vivo zebrafish angiogenic assay. Adult male and female zebrfish were placed in spawning baskets. Newly fertilized eggs were collected soon after fertilization and rinsed at 28°C in embryo water (Milli-Q water with 60 mg/l Instant Ocean-Spectrum Brands) and immediately followed by incubation in 1% methylene blue in embryo water at 28°C for 24 h. After which the embryos were dechorionated and allowed to develop in embryo water alone for 24 h (48 h post fertilization). Following this the embryos were incubated in embryo water alone or embryo water supplemented with 10 pmol db34a or dbSCR RNA, 5 µM sunitinib or a 1:1,000 dilution of DMSO as vehicle control at 28°C. After 24 h treatment, the 72 h old embryos were fixed in 10% buffered formaldehyde at room temperature for 10 min. The fixed embryos were mounted on glass slides and the completeness of sub-intestinal vein (SIV) vasculature was observed by the detection of G-RCFP using
fluorescent inverted microscopy. The significance of differences of each treatment group compared to control was determined using one-way ANOVA.

Statistical analysis. P<0.05 was considered to indicate a statistically significant difference. The difference between treated and control groups with reference to db34a/lpp RNA was analyzed using one-way ANOVA. For the angiogenesis array, significant differences between dbSCR and db34a conditioned media were analyzed using one-way ANOVA. For the macrophage assay, significant differences between macrophages grown in dbSCR and db34a conditioned media were analyzed using one-way ANOVA. Data are presented as a mean ± standard error and calculations done with OriginPro version 8.6 software (OriginLab Corporation)

Results

db34a RNA harboring miR-34a-3p and miR-34a-5p shows increased stability compared with linear RNA. A circular RNA-expressing plasmid was developed to express miR-34a. This construct codes for miR-34a and a streptavidin-binding aptamer (Fig. 1A-C). The JM101Tr E. coli strain was used for the isolation of bacterial RNA. Upon circularization of the RNA, minimal degradation was observed, even after exposure to RNase-A for 24 h (Fig. 1D). Stability was quantified using the 2^ΔΔCq method. A statistically significant difference between the control and RNase A-treated groups was detected (P=1.41627x10^-4) with reference to linear lpp RNA vs. db34a RNA. The isolated db34a and dbSCR were characterized using urea-PAG electrophoresis. Using the modified RNASwift protocol, isolation of the circular RNAs was successfully achieved, as indicated by the low-molecular-weight bands in the urea gel (Fig. 1E). To confirm that the circular forms that were isolated were indeed db34a, northern blotting was performed using a biotinylated probe specific for miR-34a. The northern blotting results show the presence of a band for each db34a group, confirming that the methodology was specific (Fig. 1F).

db34a RNA harboring miR-34a-3p and miR-34a-5p induces the expression of C-C motif chemokine ligand 5 (CCL5) in PANC-1 and MIA PaCa-2 pancreatic cancer cells. To evaluate the expression of pro-angiogenic molecules, the RayBio Human Angiogenesis Array C1 kit was used. Conditioned media collected from untransfected and db34a- or dbSCR-transfected MIA PaCa-2 and PANC-1 cells were analyzed using the array kit. From the array data, it was observed that CCL5 was significantly upregulated in PANC-1 (P=0.0028) and MIA PaCa-2 (P=0.0034) cells transfected with db34a compared with the respective dbSCR-transfected cells. Interestingly, basic fibroblast growth factor (bFGF) was also upregulated in PANC-1 and MIA PaCa-2 cells transfected with db34a, however, the upregulation was significant only in the MIA PaCa-2 cells (P=0.012; Fig. 2).

Db34a RNA harboring miR-34a-3p and miR-34a-5p suppresses angiogenic induction in HUVECs. An angiogenic tube formation assay was performed using HUVECs according to a previously described protocol (26). The assay was used to determine whether db34a has the ability to alter the angiogenic potential of PANC-1 and MIA PaCa-2 cells. In this in vitro angiogenic assay, it was observed that HUVECs treated with conditioned media from db34a-transfected PANC-1 and MIA PaCa-2 cells exhibited suppressed angiogenic potential when compared with control (PANC-1, 17.35±2.66%; MIA PaCa-2, 37±2.41%; P=0.0001; Fig. 3A and B).

db34a RNA harboring miR-34a-3p and miR-34a-5p suppresses angiogenic induction in zebrafish embryos.
Figure 3. Inhibition of angiogenesis by db34a in *in vitro* and *in vivo* models. (A) and (B) Endothelial cell tube formation assay was performed using HUVECs as a measure of angiogenesis. Phase contrast and calcein AM stained fluorescent microscope images showing reduced angiogenic tubule formation in HUVECs incubated with conditioned media from MIA PaCa-2 and PANC-1 cell lines transfected with db34a when compared with dbSCR control for 3 h. Scale bar, 200 µm. (C) *In vivo* angiogenesis assay was performed in zebrafish embryos with analysis using a fluorescent microscope. Dechorionated embryos were allowed to develop for 72 h then placed in embryo water alone (control), or supplemented with 10 pmol db34a or dbSCR RNA, 5 µM sunitinib or a 1:1,000 dilution of DMSO. The db34a-treated zebrafish embryos exhibited a reduction in the completeness of the SIV when compared with dbSCR and the controls. (D) Measurement of SIV completeness by the quantification of fluorescent intensity values of identical SIV areas and presented as a percentage of the control (control vs. db34a, P=0.043; control vs. sunitinib; P=0.025). HUVECs, human umbilical vein endothelial cells; db34a, miR-34a-3p and -5p dumbbell RNA; dbSCR, scrambled dumbbell RNA; SIV, sub-intestinal vein.
Zebrafish strain y1tg that expresses a green fluorescent protein in the vasculature was used as a model organism. SIV vasculature was observed 24 h after treatment with 10 pmol db34a or dbSCR RNA, 5 µM sunitinib or a 1:1,000 dilution of DMSO, and images were captured using a fluorescent microscope (Fig. 3C). It was observed that the embryos treated with db34a showed reduced SIV integrity compared with the controls (58.9±7.59% of the untreated control; P=0.043), which confirmed the functionality of db34a and indicated the potential of dbRNA as a therapeutic agent. Positive control embryos treated with sunitinib also exhibited decreased SIV vasculature (47.4±3.63% of the untreated control; P=0.025).

db34a RNA harboring miR‑34a‑3p and ‑5p dumbbell RNA; dbSCR, scrambled dumbbell RNA; IL, interleukin; CCL5, C‑C motif chemokine ligand 5; CXCL12α, C-X-C motif chemokine ligand 12α.

**Table I. Cytokines significantly different between macrophages treated with conditioned media from PANC-1 and MIA PaCa-2 cell lines transfected with db34a compared with dbSCR.**

| Cytokine                  | PANC-1 (fold change vs. control) | P-value | MIA PaCa-2 (fold changes vs. control) | P-value |
|---------------------------|----------------------------------|---------|--------------------------------------|---------|
| CD30 ligand (TNFSF8)      | 1.543449                         | 4.61297×10⁻⁵ | 1.808521                            | -       |
| Fractalkine (CX3CL1)      | 1.591752                         | 0.00309 | 0.798687                             | -       |
| IFN-γ                     | 5.434441                         | 0.02768 | 1.484371                             | -       |
| IL-1α (IL-1 F1)           | 1.793997                         | 0.02553 | 1.287388                             | -       |
| IL-1β (IL-1 F2)           | 5.106111                         | 0.0092  | 0.943795                             | -       |
| IL-2                      | 2.601422                         | 0.04669 | 0.909556                             | -       |
| IL-6                      | 3.973113                         | 0.02473 | 1.081643                             | -       |
| IL-10                     | 7.051837                         | 0.00978 | 0.605812                             | -       |
| IL-12 p70                 | 6.513021                         | 0.02201 | 0.673057                             | -       |
| IL-13                     | 2.100802                         | 0.00251 | 1.849357                             | 0.00994 |
| IL-17A                    | 3.668945                         | 0.00847 | 3.655409                             | 0.03355 |
| I-TAC (CXCL11)            | 1.996696                         | 0.02114 | 2.297556                             | -       |
| KC (CXCL1)                | 1.596054                         | 0.0123  | 2.07834                              | -       |
| Leptin                    | 4.536913                         | 0.0375  | 2.313414                             | -       |
| LIX (CXCL5)               | 1.252327                         | -       | 1.334515                             | 0.02446 |
| M-CSF                     | 1.339565                         | 0.02349 | 1.40063                              | 0.03974 |
| RANTES (CCL5)             | 2.056593                         | 0.00633 | 2.646111                             | 0.00422 |
| SDF-1α (CXCL12α)          | 2.493808                         | 0.00911 | 1.820613                             | 0.01686 |
| I-309 (TCA-3/CCL1)        | 1.689148                         | 0.00128 | 1.319467                             | 0.00263 |
| TECK (CCL25)              | 1.635333                         | 0.02981 | 1.637408                             | 0.02115 |
| TIMP-2                    | 1.091021                         | -       | 1.089587                             | 0.04152 |
| TNF-α                     | 1.387676                         | 4.64829×10⁻⁴ | 2.003669                          | 0.02406 |
| TNF RI (TNFRSF1A)         | 1.355374                         | 0.02447 | 1.223076                             | 0.02037 |
| TNF RII (TNFRSF1B)        | 1.114493                         | -       | 1.962633                             | 0.00873 |

**Discussion**

Despite decades of research, the treatment of pancreatic ductal adenocarcinoma continues to be a major challenge. According to the American Cancer Society, for all stages of pancreatic cancer combined, the 1-year survival rate is ~20% and the 5-year survival rate is 9% (28). One of the major factors that contributes to this poor prognosis is late detection, as early-stage pancreatic cancer is usually asymptomatic (29). New surgical techniques and evolving therapeutics have achieved only modest outcomes (30). A clearer understanding of targetable molecular pathways is required to design therapeutic agents and achieve a desired clinical outcome. Non-coding RNAs such as miRNAs play important roles in the regulation of gene expression. Unlike siRNAs, miRNAs target multiple genes and are usually process specific (31). Most biological processes are in some way regulated by miRNAs, which are small RNA molecules ~22 nucleotides in length that probably
GNANAMONY et al: db34a MEDIATES ANGIOGENIC SUPPRESSION AND MACROPHAGE ACTIVATION

The mechanisms of miRNA action have been elucidated, although not completely (33). Their capacity to regulate mRNAs and other miRNAs is being reported with increasing frequency, and they have become powerful tools for gene regulation. The use of RNA molecules to target angiogenesis continues to be explored (11-16). However, the approach described in the present study, utilizing a circular RNA molecule with two miRs is novel and, to the best of our knowledge, has not been described previously. The approach was to develop a closed circular RNA coding for miRNAs. A circular RNA is not readily degraded by exonucleases and the inherent higher stability of dsRNAs compared with ssRNAs may contribute to an increased half-life (34). Increased stability of db34a compared with linear RNA was observed in the present study. To the best of our knowledge, the present study is the first to use closed circular dbRNAs to code for both miR34-3p and -5p simultaneously with a therapeutic intention.

The present study aimed to demonstrate that circular RNA harboring miRs are functional and have significant therapeutic potential using dbRNA encoding miR-34a-3p and -5p. To construct the circular RNA expressing miR-34a-3p and -5p, the PIE method was used, which is an enzyme-free RNA circularization method based on group I intron self-splicing (17), which can be conducted using essentially any type of cell. Cells transcribe more RNA than they accumulate (35). This indicates that RNA is constantly being degraded and that a dynamic process occurs to balance RNA synthesis and degradation. The use of siRNA therapeutically is not new but has the limitations of low half-life and questionable in vivo efficacy (36,37), which is mainly due to the effects of exonuclease RNases. The present study circumvents the problem of a low half-life by designing dbRNAs that should not be degraded by the exonuclease activity of RNases. A previous study demonstrated the stability of a 35mer FITC-labeled RNA in the presence of circular dbRNA/DNA chimeric oligonucleotides to RNase H. This induced stability is most likely due to the competition of RNA/DNA chimeric with the 35mer FITC-labeled RNA (38). The stability experiments conducted in the present study demonstrate that circular RNA exposed to RNase A for 24 h was more stable than linear RNA driven by the same lpp promoter (18,24). Gene silencing by siRNA/miRNAs can be used as a therapeutic approach for the treatment of un-druggable targets. Researchers have also shown that dumbbell-shaped DNA minimal vectors can be used for small hairpin RNA expression (39,40). These studies also demonstrated the use of a dumbbell DNA vector to produce hairpin RNAs that can be used therapeutically. Another study described the generation of dumbbell-shaped nano-circular RNAs for RNA interference, using a chemical method of synthesis involving the enzyme-based circularization of small RNA molecules (41). By contrast, the present study reveals the development of a larger dbRNA and is unique in that it uses a bacterial system for large-scale dbRNA production.

Although not much is known about miR-34a-3p, miR-34a-5p is well studied and has been shown to be involved in tumor suppression, angiogenic suppression and cancer stem cell suppression (42-49); hsa-miR-34a-3p was previously known...
as hsa-miR-34a* and hsa-miR-34a-5p was previously known hsa-miR-34a. It was recently demonstrated that normal cells do show detectable expression levels of miR34a (50). Normal cell lines were not used in the present study and this is a limitation of the study. Since normal cells do show detectable levels of miR34a, the addition of db34a to normal cells should not, in theory, induce a notable perturbation in the existing molecular pathways of normal cells; this however requires further study. To demonstrate the possibility of using circular RNA therapeutically, in the present study circular miR-34a-3p and -5p were transfected into pancreatic cancer cells and the expression of pro-angiogenic molecules was determined. It was observed that in the two pancreatic cancer cell lines transfected with db34a, the expression levels of bFGF and CCL5 were significantly increased. miR-34a-5p expression is known to be increased by the activation of the PI3K signaling pathway (51) and, notably, mir-34a-5p has been shown to suppress the PI3K signaling pathway (52-56). These contradictory observations indicate the possibility of the existence of a tight regulatory apparatus that is not yet clearly understood. Interestingly, TNF is predicted as the target of hsa-miR-34a-3p by the miRDB online database, and TNF is a strong promoter of angiogenesis (57). This indicates that hsa-miR-34a-3p may be more therapeutically relevant in angiogenic suppression. It should be noted that both miR-34a-3p and miR-34a-5p are processed from the same pre-miR. This is consistent with the observation that angiogenesis was suppressed significantly in the in vitro and in vivo angiogenic assays of the present study. This observation appears contrary to the expected outcome; however, miR-34a-5p is a known angiogenic suppressor (43) and the quantification of other relevant angiogenesis-associated molecules will provide a clearer mechanistic profile of this angiogenesis modulation. Every biological process in an oncogenic system is tightly regulated; therefore, targeting a process rather than a single molecule would not be clinically relevant as compensatory pathways can be activated to achieve the oncogenic phenotype. The overexpression of bFGF may be one such compensatory response, which is seen in both pancreatic cell lines.

The present study also demonstrated that CCL5 is significantly upregulated in PANC-1 and MIA PaCa-2 cells transfected with db34a. CCL5, also known as regulated on activation, normal T cell expressed and secreted (RANTES), is a chemokine that is involved in T-cell activation. RANTES has been identified as a major HIV-suppressive factor. Studies have shown that recombinant human RANTES induces a dose-dependent inhibition of different strains of HIV-1, HIV-2 and simian immunodeficiency virus (SIV) (58,59). The expression of CCL5 in MIA PaCa-2 and PANC-1 cells transfected with db34a RNA indicates the involvement of a conserved pathway. Additionally, research is necessary to determine whether transfection with db34a can also induce the overexpression of CCL5 in other types of cells. In a recent study, it was shown that CCL5 and CCR5 expression levels are increased in pancreatic cancer tissue sections, and the overexpression of CCL5 and CCR5 increases the invasiveness and metastatic potential of pancreatic cancer cells (60). It has also been reported that progranulin (PGRN) expression levels correlate with a poor prognosis for melanoma patients, and PGRN inhibits CCL5 gene expression at the transcriptional level, showing that CCL5 is responsible for the recruitment of activated natural killer cells to the tumor microenvironment (61). Another study highlighted the importance of CCL5, demonstrating that the blockade of 1,4-α-glucan-branching enzyme in lung cancer cells promoted the secretion of CCL5, which induced the recruitment of CD8+ T lymphocytes to the tumor microenvironment (62). CCL5 expression has also been shown to restore the immune surveillance in antigen-expressing MYC;CTNNB1 hepatocellular carcinoma tumors (63). This indicates that CCL5 is necessary for tumor cells to be visible to the immune system; especially, CCL5 expression is necessary for immune recognition. However, it is also important to note that CCL5 was recently identified as a signature of poor prognosis for oral squamous cell carcinoma, indicating its multifaceted role (64). Interestingly, another study observed that the expression of CCL5 in breast cancer cells was associated with lymph node status and tumor node-metastasis stage (65). The conflicting roles of CCL5, and whether its overexpression is a predisposing factor for poor prognosis or a response to poor prognosis remains unclear. The association of CCL5 with other immune-associated molecules may provide clearer insight, and CCL5 expression alone should not be used as a measure of prognosis.

Furthermore, the present study investigated whether the transfection of pancreatic cancer cells with db34a induces the activation of immune cells. It was observed that the conditioned medium from db34a-transfected pancreatic cancer cells significantly induced the expression of IL-13, CCL5 and CXCL12α among other inflammatory response genes in mouse macrophage cell lysates. Tumor-associated macrophages (TAMs) are present in high numbers in the microenvironment of solid tumors and have been studied for their potential as targets for cancer therapy (66). TAMs suppress host immune responses and also promote tumor cell proliferation, angiogenesis, invasion and metastasis (67). The role of TAMs remains unclear; however, most evidence suggests that TAMs promote tumor progression. From the data in the present study, especially the overexpression of IL-13, it appears that the J774A.1 macrophages expressed conditioned medium from db34a-transfected pancreatic cancer cells appeared more closely associated with the M1 phenotype than the M2 phenotype (data not shown) (68). Further investigation is required to decipher the influence of db34a on macrophages.

In conclusion, the present data suggest that the supplementation of miR-34a-3p and -5p as a circular pre-miR form is a viable method of miR replacement therapy.

Acknowledgements

Assistance for the maintenance of Zebrafish culture at the Laboratory Animal Care Facility, UICOMP, LACF-Peoria IL, by Laboratory Animal Care Supervisor Ms. Angela Daniels and, Laboratory Animal Care Technician Ms. Stephanie Sampson is acknowledged.

Funding

The Department of Internal Medicine, University of Illinois College of Medicine at Peoria; McElroy Foundation (Springfield, IL, USA) (grant no, 096726) and gift from The
Theresa Tracy Strive to Survive Foundation (East Peoria, IL, USA) supported the present study.

Availability of data and materials

The plasmid constructs db34a and dbSCR are available from the corresponding author upon reasonable request in accordance with institutional MTA approvals and all applicable rules and regulations. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MG designed and performed experiments and reviewed the manuscript. LD validated the constructs, designed the RNA stability experiments, confirmed dbRNA stability and quantified data. LG and PS were involved in designing the concept of the study. SB was involved in RNA experiments and data collection. JAN was involved in zebrafish data collection. CSG designed, and developed the concept and experiments, and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All experimental procedures using zebrafish were performed with approval from the Institutional Animal and Use Committee of University of Illinois College of Medicine at Peoria.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
2. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424, 1998.
3. Folkman J: Antiangiogenic gene therapy. Proc Natl Acad Sci USA 95: 9064-9066, 1998.
4. Dommez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagöz F and Kandemir B: Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205: 854-7, 2009.
5. Neves KB, Montezano AC, Lang NN and Touyz RM: Vascular endothelial growth factor pathway: A phase II study of AZD2171 (cediranib) in treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma 56: 2503-20, 2020.
6. Mattsson R, Jumonville A, Flynn PJ, Moreno-Aspitia A, Erlichman C, LaPlant B and Juckett MB: A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma 56: 2061-2066, 2015.
7. Hong DS, Garrido-Laguna I, Ekmeckioğlu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimeridou AM, et al: Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120: 2164-2173, 2014.
8. Liu JF, Tolaney SM, Birrer M, Fleming G, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, et al: A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49: 2972-2978, 2013.
9. Climent-Salarich M, Quintavalle M, Miragoli M, Chen J, Condorelli G and Elia L: TGFB triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Curr Res Circ 116: 1753-1764, 2015.
10. Huang G and Chen L: Tumor vasculature and microenvironment normalization: A possible mechanism of antiangiogenesis therapy. Cancer Biother Radiopharm 23: 661-667, 2008.
11. Babas AS and White RR: The development and testing of aptamers for cancer. Curr Opin Investig Drugs 10: 572-578, 2009.
12. Guggiari-Melloni T, Bringhen S and Palumbo A: Update on the use of defibrotide. Expert Opin Biol Ther 12: 353-361, 2012.
13. Gatto B and Cavalli M: From proteins to nucleic acid-based drugs: The role of biotech in anti-VEGF therapy. Anticancer Agents Med Chem 6: 287-301, 2006.
14. Kanwar JR, Mahidhara G and Kanwar RK: Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov Today 16: 188-202, 2011.
15. Friedman AD, Kim D and Liu R: Highly stable aptamers selected from a 20-fully modified GmH RNA library for targeting biomaterials. Biomaterials 36: 110-23, 2015.
16. Inoue M, Kadonosono K, Arakawa A, Yamane S and Ishibashi T: Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol 59: 173-178, 2015.
17. Putraju M and Been MD: Circular ribozymes generated in Escherichia coli using group I self-splicing permuted intron-exon sequences. J Biol Chem 271: 26081-26087, 1996.
18. Umekage S and Kikuchi Y: In vivo circular RNA production using a constitutive promoter for high-level expression. J Biosci Bioeng 108: 354-356, 2009.
19. Ford E and Ares M Jr: Synthesis of circular RNA in bacteria and yeast using RNA cyclase ribozymes derived from a group I intron of phage T4. Proc Natl Acad Sci USA 91: 3117-3121, 1994.
20. Ponchon L and DardeI F: Recombinant RNA technology: The RNA scaffold. Nat Methods 4: 571-576, 2007.
21. Umekage S and Kikuchi Y: In vitro and in vivo production and purification of circular RNA aptamer. J Biotechnol 139: 265-272, 2009.
22. Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415, 2003.
23. Nwokeoji AO, Kilby PM, Portwood DE and Dickman MJ: RNAsWift: A rapid, versatile RNA extraction method free from phenol and chloroform. Anal Biochem 512: 36-46, 2016.
24. Chen QX, Wang WP, Zeng S, Urayama S and Yu AM: A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res 43: 3878-3895, 2015.
25. Livak KJ, Schmittgen TD: Analysis of relative gene expression using real-time quantitative PCR and the 2(-delta delta CT) method. Methods 25: 402-408, 2001.
26. Friedman AD, Kim D and Liu R: Highly stable aptamers selected from a 20-fully modified GmH RNA library for targeting biomaterials. Biomaterials 36: 110-23, 2015.
27. Ford E and Ares M Jr: Synthesis of circular RNA in bacteria and yeast using RNA cyclase ribozymes derived from a group I intron of phage T4. Proc Natl Acad Sci USA 91: 3117-3121, 1994.
28. Ponchon L and DardeI F: Recombinant RNA technology: The RNA scaffold. Nat Methods 4: 571-576, 2007.
29. Umekage S and Kikuchi Y: In vitro and in vivo production and purification of circular RNA aptamer. J Biotechnol 139: 265-272, 2009.
30. Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415, 2003.
31. Gnanamony et al: db34a MEDIATES ANGIogenic SUPPRESSION AND MACROPHAGE ACTIVATION

10
43. Zhai L, Zhao Y, Liu Z, Wu J and Lin L: mRNA expression profile analysis reveals a C-MYC/miR-34a pathway involved in the apoptosis of diffuse large B-cell lymphoma cells induced by yiqichutan treatment. Exp Ther Med 20: 2157-2165, 2020.

52. Li J, Mohammed-Elbach M, Pacezhowski F and Li Y: Circular nucleic acids: Discovery, functions and applications. ChemBiochem 21: 1547-1566, 2020.

45. Houseley J and Tollervey D: The many pathways of RNA degradation. Cell 136: 763-776, 2009.

46. Ryther RC, Flynt AS, Phillips JA III and Patton JG: siRNA therapeutics: Big potential from small RNAs. Gene Ther 12: 5-11, 2005.

47. Bakhtiyari S, Haghani K, Basati G and Karimfar MH: siRNA therapeutics in the treatment of diseases. Ther Deliv 4: 45-57, 2013.

48. Park WS, Miyano-Kurosaki N, Abe T, Takai K and Takaku H: Properties of circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides. Nucleic Acids Symp Ser: 225-226, 1999.

49. Yu H, Jiang X, Tan KT, Hang L and Patel V: Efficient design of superior dumbbell-shaped DNA minimal vectors for small hairpin RNA expression. Nucleic Acids Res 43: e120, 2015.

50. Jiang X, Yu H, Teo CR, Tan GS, Goh SC, Patel P, Chua YK, Hameed NB, Bertolotti A and Patzel V: Advanced design of dumbbell-shaped genetic minimal vectors improves non-coding and coding RNA expression. Mol Ther 24: 1581-1591, 2016.

51. Abe N, Abe H, Nagai C, Harada M, Hatakeyama H, Yoshimura M, Furukawa K, Maeda M, et al: Synthesis, structure, and biological activity of dumbbell-shaped nano-circular RNAs for RNA interference. Bioconjug Chem 22: 2082-2092, 2011.

52. Misso G, Di Martino MT, De Rosa G, Farrooqi AA, Lombardi A, Campani V, Zarone MR, Guilla A, Tagliaferri P, Tassone P and Caraglia M: Mir-34: A new weapon against cancer? Mol Ther Nucleic Acids 3: e194, 2015.

53. Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A potential therapeutic target in human cancer. Cell Death Dis 5: e1327, 2014.

54. Kofman AV, Kim J, Park SY, Dupart E, Letson C, Bao Y, Ding K, Chen Q, Schaff D, Lerner J and Abounader R: microRNA-34a promotes DNA damage and mitotic catastrophe. Cell Cycle 12: 3500-3511, 2013.

55. Kumar B, Yadav A, Lang J, Teknos TN and Kumar P: Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One 7: e37601, 2012.

56. Tivan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM and Stallings RL: MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 11: 33, 2011.

57. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J and Monzo M: mir-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30: 1903-1909, 2009.

58. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J and Khan J: The MYCN oncogene is a direct target of miR-34a. Oncogene 27: 5204-5213, 2008.

59. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, Ingenito GT, Gerin I, Feng Y, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al: p53-mediated activation of miRNA-343 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307, 2007.

60. Bozgeyik E, Tepe NB and Bzdag Z: Identification of microRNA expression signature for the diagnosis and prognosis of cervical squamous cell carcinoma. Pathol Res Pract 216: 153159, 2020.

61. Barnes PJ, Baker J and Donnelly LE: Cellular senescence as a mechanism and target in chronic lung diseases. Am J Respir Crit Care Med 200: 556-564, 2019.

62. Zhai L, Zhao Y, Liu Z, Wu J and Lin L: mRNA expression profile analysis reveals a C-MYC/miR-34a pathway involved in the apoptosis of diffuse large B-cell lymphoma cells induced by yiqichutan treatment. Exp Ther Med 20: 2157-2165, 2020.